Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term OVARIAN-CANCER. Found 17 abstracts

Angevin E, Tabernero J, Elez E, Cohen SJ, Bahleda R, van Laethem JL, Ottensmeier C, Lopez-Martin JA, Clive S, Joly F, Ray-Coquard I, Dirix L, Machiels JP, Steven N, Reddy M, Hall B, Puchalski TA, Bandekar R, de Velde HV, Tromp B, Vermeulen J, Kurzrock R. A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors. Clinical Cancer Research. 2014 Apr;20(8):2192-204.   PMCID: No NIH funds
Hesterberg PE, Banerji A, Oren E, Penson RT, Krasner CN, Seiden MV, Wong JT. Risk stratification for desensitization of patients with carboplatin hypersensitivity: Clinical presentation and management. Journal of Allergy and Clinical Immunology. 2009 Jun;123(6):1262-7.
Huo DZ, Senie RT, Daly M, Buys SS, Cummings S, Ogutha J, Hope K, Olopade OI. Prediction of BRCA Mutations Using the BRCAPRO Model in Clinic-Based African American, Hispanic, and Other Minority Families in the United States. Journal of Clinical Oncology. 2009 Mar;27(8):1184-90.   PMCID: PMC2667822
Levina VV, Nolen B, Su Y, Godwin AK, Fishman D, Liu JS, Mor G, Maxwell LG, Herberman RB, Szczepanski MJ, Szajnik ME, Gorelik E, Lokshin AE. Biological Significance of Prolactin in Gynecologic Cancers. Cancer Research. 2009 Jun;69(12):5226-33.   PMCID: PMC2918393
Timakhov RA, Tan YF, Rao M, Liu ZM, Altomare DA, Pei JM, Wiest DL, Favorova OO, Knepper JE, Testa JR. Recurrent Chromosomal Rearrangements Implicate Oncogenes Contributing to T-Cell Lymphomagenesis in Lck-MyrAkt2 Transgenic Mice. Genes Chromosomes & Cancer. 2009 Sep;48(9):786-94.   PMCID: PMC 2739734
Bradbury AR, Ibe CN, Dignam JJ, Cummings SA, Verp M, White M, Artioli G, Dudlicek L, Olopade OL. Uptake and timing of bilateral prophylactic salpingo-oophorectomy among BRCA1 and BRCA2 mutation carriers. Genetics in Medicine. 2008 Mar;10(3):161-6.
Eisen A, Lubinski J, Gronwald J, Moller P, Lynch HT, Klijn J, Kim-Sing C, Neuhausen SL, Gilbert L, Ghadirian P, Manoukian S, Rennert G, Friedman E, Isaacs C, Rosen E, Rosen B, Daly M, Sun P, Narod SA, Hereditary Breast Canc Clinical S. Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. Journal of the National Cancer Institute. 2008 Oct;100(19):1361-7.
Kauff ND, Domchek SM, Friebel TM, Robson ME, Lee J, Garber JE, Isaacs C, Evans DG, Lynch H, Eeles RA, Neuhausen SL, Daly MB, Matloff E, Blum JL, Sabbatini P, Barakat RR, Hudis C, Norton L, Offit K, Rebbeck TR. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: A multicenter, prospective study. Journal of Clinical Oncology. 2008 Mar;26(8):1331-7.
Apicella C, Dowty JG, Dite GS, Jenkins MA, Senle RT, Daly MB, Andrulis IL, John EM, Buys SS, Li FP, Glendon G, Chung W, Ozcelik H, Miron A, Kotar K, Southey MC, Foulkes WD, Hopper JL. Validation study of the LAMBDA model for predicting the BRCA1 or BRCA2 mutation carrier status of North American Ashkenazi Jewish women. Clinical genetics. 2007 Aug;72(2):87-97.
Bane AL, Beck JC, Bleiweiss I, Buys SS, Catalano E, Daly MB, Giles G, Godwin AK, Hibshoosh H, Hopper JL, John EM, Layfield L, Longacre T, Miron A, Senie R, Southey MC, West DW, Whittemore AS, Wu H, Andrulis IL, O'Malley FP. BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays. American Journal of Surgical Pathology. 2007 Jan;31(1):121-8.
Carvalho MA, Marsillac SM, Karchin R, Manoukian S, Grist S, Swabym RF, Urmenyi TP, Rondinelli E, Silva R, Gayol L, Baumbach L, Sutphen R, Pickard-Brzosowicz JL, Nathanson KL, Sali A, Goldgar D, Couch FJ, Radice P, Monteiro AN. Determination of cancer risk associated with germ line BRCA1 missense variants by functional analysis. Cancer Research. 2007 Feb;67(4):1494-501.
Friebel TM, Domchek SM, Neuhausen SL, Wagner T, Evans DG, Isaacs C, Garber JE, Daly MB, Eeles R, Matloff E, Tomlinson G, Lynch HT, Tung N, Blum JL, Weitzel J, Rubinstein WS, Ganz PA, Couch F, Rebbeck TR. Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers. Clinical Breast Cancer. 2007 Dec;7(11):875-82.
Manne SL, Chung DC, Weinberg DS, Vig HS, Catts Z, Cabral MK, Shannon K, Meropol NJ. Knowledge and attitudes about Microsatellite instability testing among high-risk individuals diagnosed with colorectal cancer. Cancer Epidemiology Biomarkers & Prevention. 2007 Oct;16(10):2110-7.
Murph M, Tanaka T, Pang J, Felix E, Liu S, Trost R, Godwin AK, Newman R, Mills G. Liquid chromatography mass spectrometry for quantifying plasma lysophospholipids: Potential biomarkers for cancer diagnosis. Methods in Enzymology . 2007 Jan;433:1-25.
Halbert RJ, Figlin RA, Atkins MB, Bernal M, Hutson TE, Uzzo RG, Bukowski RM, Khan KD, Wood CG, Dubois RW, Peacock S, Apicella C, Andrews L, Tucker K, Bankier A, Daly MB, Hopper JL. Treatment of patients with metastatic renal cell cancer - A RAND appropriateness panel. A discrete choice experiment of preferences for genetic counselling among Jewish women seeking cancer genetics services. Cancer. 2006 Nov;95(10):1448-53.
Valicenti RK, DeSilvio M, Hanks GE, Porter A, Brereton H, Rosenthal SA, Shipley WU, Sandler HM, Haile RW, Thomas DC, McGuire V, Felberg A, John EM, Milne RL, Hopper JL, Jenkins MA, Levine AJ, Daly MM, Buys SS, Senie RT, Andrulis IL, Knight JA, Godwin AK, Southey M, McCredie MR, Giles GG, Andrews L, Tucker K, Miron A, Apicella C, Tesoriero A, Bane A, Pike MC, Whittemore AS. Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: An analysis of radiation therapy oncology group protocol 92-02 BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Article DE prostate cancer; prostate-specific antigen doubling time; mortality; surrogate endpoint. 2006 Oct;15(10):1863-70.
Roland IH, Yang WL, Yang DH, Daly MB, Ozols RF, Hamilton TC, Lynch HT, Godwin AK, Xu XX. Loss of surface and cyst epithelial basement membranes and preneoplastic morphologic changes in prophylactic oophorectomies. Cancer. 2003 Dec;98(12):2607-23.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term OVARIAN-CANCER

OVARIAN-CANCER WOMEN RISK CELLS BREAST-CANCER BRCA2 breast cancer REDUCTION COMMON BRCA1 FOLLOW-UP BREAST-CANCER RISK ENDOMETRIAL CANCER PENETRANCE PREVALENCE BRCA1 ESTROGEN-RECEPTOR STATUS EXPRESSION CARCINOMA SURGERY POPULATION GERMLINE MUTATIONS time to PSADT (assuming first-order kinetics for a minimum of 3 rising REGISTRY on Radiation Therapy Oncology Group Protocol 92-02 From June 1992 to mutations ACTIVATION GENE MUTATION TERMINAL REGION ANAPHYLAXIS prophylactic salpingo-oophorectomy SALPINGO-OOPHORECTOMY PSA measurements) and cancer-specific survival (CSS) GROWTH-HORMONE ORAL-CONTRACEPTIVES FAILURE neoplasm metastasis IN-VIVO CARRIER PROBABILITIES PHOSPHOPEPTIDE RECOGNITION KeyWords Plus: HEALTH-CARE RECURRENCE PROSTAGLANDIN E-2 basement membrane (T2c-4 and PSA level < 150 ng INDUCTION TRANSCRIPTION TRIAL DEATH immunotherapy LYNCH-SYNDROME CHEMOTHERAPY FAMILY-HISTORY (P-Cox = 04) The significant posttreatment PSADTs were also CARRIERS INFORMATION HIGH-DOSE THERAPY biomarkers MESSENGER-RNA CISPLATIN Ashkenazi C-MYC ONCOGENE K-RAS significant predictors of CSS (P-Cox < 0001) After adjusting for T SELF-EFFICACY 185DELAG (Methods and Materials: ) under bar We analyzed posttreatment PSA FAMILY REGISTRY Oncology BACH1 PHOSPHOPEPTIDE or in combination with 24 65-70 Gy of radiation therapy (n = 761) CANCER-SUSCEPTIBILITY GENES BRCA2 MUTATIONS HEALTH BELIEF MODEL CASTLEMANS-DISEASE PROTOCOL FAMILIAL BREAST BILATERAL PROPHYLACTIC OOPHORECTOMY randomized treatment was a significant predictor for CSS (p(Cox) = months of adjuvant androgen deprivation (n = 753) Using an adjusted SURVIVAL TAMOXIFEN men were randomized to neoadjuvant androgen deprivation and April 1995 MUTATIONS GROWTH surgery TRANSCRIPTIONAL ACTIVATION MANAGEMENT the risk of dying requirements for a surrogate endpoint of CSS Thus surrogate endpoint OUTCOMES BONE-MARROW AUTOTRANSPLANTS but did not meet all of Prentice's significantly associated with CSS INTERLEUKIN-2 discrete choice experiment MAMMALIAN OVULATION DNA-SEQUENCE VARIANTS PLUS INTERFERON-ALPHA YOUNG-WOMEN LYSOPHOSPHATIDIC ACID PRODUCTION collagen IV NONCARRIERS AKT PROTEIN-KINASE-B IMMUNOHISTOCHEMICAL MARKERS pathology HUMAN BREAST-CARCINOMA ALLERGY genetic testing BLOOD-CELL the randomized treatment TUMOR SUPPRESSION AUTOTAXIN NPP-2 epithelium OOPHORECTOMY CYCLOOXYGENASE-2 COX-2 premalignant lesion familial PACLITAXEL laminin PROGNOSIS INDIVIDUALS SURGICAL ADJUVANT BREAST BRCA1 and BRCA2 RISK AB (Purpose:) under bar We evaluated whether posttreatment ovarian JEWS Gleason score and PSA stage-all of Prentice's requirements were not angiogenesis Ashkenazi Jewish INTERLEUKIN-6 ovarian carcinoma genetics indicating that the effect of PSADT on CSS was not independent of met of prostate cancer is not fully explained by PSADT (c) 2006 Elsevier UNKNOWN CLINICAL-SIGNIFICANCE QUANTITATIVE-ANALYSIS GENE TUMOR CHARACTERISTICS PHENOTYPE RADICAL PROSTATECTOMY Inc BRCA2 MUTATION CARRIERS (Results: ) under bar After a median follow-up time of 59 years REPLACEMENT TRANSGENIC MICE ADHERENCE drug allergy Desensitization-carboplatin-ovarian cancer-skin testing-hypersensitivity EXPERIENCE MEASURES
Last updated on Friday, August 07, 2020